Brief: Vaxart Provides Business Update, Reports Third Quarter 2022 Financial Results

Vaxart

08/11/2022 23:07

Nov 8 (Reuters) - Vaxart Inc  VXRT.O :
    * VAXART PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER
2022
FINANCIAL RESULTS
    * NET LOSS PER SHARE FOR Q3 OF 2022 WAS $0.23
    * START OF PHASE II TRIAL OF VAXART'S BIVALENT NOROVIRUS
VACCINE
CANDIDATE IN Q4 2022 OR Q1 2023
    * SELECTION OF COVID-19 VACCINE CONSTRUCT TO BE USED IN UK
HUMAN
CHALLENGE STUDY EXPECTED IN Q4 2022
    * TOP-LINE DATA FROM ONGOING PHASE II NOROVIRUS CHALLENGE
STUDY
EXPECTED AT END OF Q1 2023 OR EARLY Q2 2023
    * Q3 EARNINGS PER SHARE VIEW $-0.24 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXx1xL5 
Further company coverage:  VXRT.O 
 ((Reuters.Briefs@thomsonreuters.com;))